scholarly journals Blood-based protein mediators of senility with replications across biofluids and cohorts

2019 ◽  
Vol 2 (1) ◽  
Author(s):  
Donald R Royall ◽  
Raymond F Palmer ◽  

Abstract Dementia severity can be quantitatively described by the latent dementia phenotype ‘δ’ and its various composite ‘homologues’. We have explored δ’s blood-based protein biomarkers in the Texas Alzheimer’s Research and Care Consortium. However, it would be convenient to replicate them in the Alzheimer’s Disease Neuroimaging Initiative. To that end, we have engineered a δ homologue from the observed cognitive performance measures common to both projects [i.e. ‘d:Texas Alzheimer’s Research and Care Consortium to Alzheimer’s Disease Neuroimaging Initiative’ (dT2A)]. In this analysis, we confirm 13/22 serum proteins as partial mediators of age’s effect on dementia severity as measured by dT2A in the Texas Alzheimer’s Research and Care Consortium and then replicate 4/13 in the Alzheimer’s Disease Neuroimaging Initiative’s plasma data. The replicated mediators of age-specific effects on dementia severity are adiponectin, follicle-stimulating hormone, pancreatic polypeptide and resistin. In their aggregate, the 13 confirmed age-specific mediators suggest that ‘cognitive frailty’ pays a role in dementia severity as measured by δ. We provide both discriminant and concordant support for that hypothesis. Weight, calculated low-density lipoprotein and body mass index are partial mediators of age’s effect in the Texas Alzheimer’s Research and Care Consortium. Biomarkers related to other disease processes (e.g. cerebrospinal fluid Alzheimer’s disease-specific biomarkers in the Alzheimer’s Disease Neuroimaging Initiative) are not. It now appears that dementia severity is the sum of multiple independent processes impacting δ. Each may have a unique set of mediating biomarkers. Age’s unique effect appears to be at least partially mediated through proteins related to frailty. Age-specific mediation effects can be replicated across cohorts and biofluids. These proteins may offer targets for the remediation of age-specific cognitive decline (aka ‘senility’), help distinguish it from other determinants of dementia severity and/or provide clues to the biology of Aging Proper.

2005 ◽  
Vol 26 (1) ◽  
pp. 1-7 ◽  
Author(s):  
Rangaraj K. Gopalraj ◽  
Haiyan Zhu ◽  
Jeremiah F. Kelly ◽  
Marta Mendiondo ◽  
Joseph F. Pulliam ◽  
...  

2008 ◽  
Vol 20 (4) ◽  
pp. 815-823 ◽  
Author(s):  
Burcu Balam Yavuz ◽  
Bunyamin Yavuz ◽  
Meltem Halil ◽  
Mustafa Cankurtaran ◽  
Zekeriya Ulger ◽  
...  

ABSTRACTBackground: Gamma glutamyltransferase (GGT) plays a role in cellular glutathione uptake, which is an important element of antioxidant mechanisms. An increase in serum GGT is thought to be an early and sensitive marker of oxidative stress. Oxidative stress has a role in the pathogenesis of Alzheimer's disease (AD). The aim of this study was to investigate the GGT levels in AD.Method: In this cross-sectional study, 132 patients with AD (mean age: 74.1 ± 7.4, female 62.9%) and 158 age- and gender-matched normal controls (mean age: 74.5 ± 6.3, female 67.1%) were evaluated. For cognitive assessment, MMSE and clock drawing tests were performed; DSM-IV and NINCDS-ADRDA criteria were used. Serum GGT, aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase concentrations were determined.Results: Median (min-max) GGT levels were 18 (9–70) in AD group and 17 (5–32) in normal controls. Mann-Whitney U test showed that GGT levels were significantly higher in AD patients (p = 0.012). Linear regression analysis revealed AD was an independent correlate of elevated GGT levels. Hypertension, diabetes mellitus, total cholesterol, and low density lipoprotein cholesterol were not associated with GGT levels.Conclusion: GGT levels were increased significantly in AD patients. To evaluate the role of GGT as a marker of oxidative stress in AD, further studies are needed.


2020 ◽  
Vol 11 (1) ◽  
pp. 116-123
Author(s):  
Pan Wang ◽  
Huihong Zhang ◽  
Yan Wang ◽  
Miao Zhang ◽  
Yuying Zhou

AbstractBackgroundThe relationship between the apolipoprotein E (APOE)-ε4 allele, triglyceride (TG) level, and cholesterol level and an increased risk of developing Alzheimer’s disease (AD) has been well established, but their relationship with behavioral-variant frontotemporal dementia (bvFTD) is not well-known.MethodologyThe levels of TGs, total cholesterol (TC), low-density lipoprotein (LDL), and high-density lipoprotein were measured in bvFTD and AD patients and in normal controls (NCs). DNA was extracted, and APOE was genotyped.ResultsThe APOE-ε4 allele frequency was higher in the AD group than in the NC group, but no difference was found between the AD and the bvFTD groups. The bvFTD group had higher LDL than the AD group, and significant differences were also found for the cholesterol level in the dementia groups compared with the NC group. Elevated LDL level was positively correlated with appetite and eating score in the bvFTD group. Compared with the AD patients and NCs without the APOE-ε4 allele, those with the APOE-ε4 allele had higher TC, but its correlation with the bvFTD group was absent.ConclusionsThe bvFTD and the AD groups had higher cholesterol levels. The APOE-ε4 allele and eating behavior might modify lipid metabolism in dementia. TG and cholesterol analyses may offer a new opportunity for targeted treatments.


2014 ◽  
Vol 35 (8) ◽  
pp. 1833-1838 ◽  
Author(s):  
Jihad Murr ◽  
Pierre-Hugues Carmichael ◽  
Pierre Julien ◽  
Danielle Laurin

Sign in / Sign up

Export Citation Format

Share Document